For the year ending 2025-12-31, APVO had $12,905K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -25,967 |
| Stock-based compensation | 96 |
| Non-cash lease expense | 1,089 |
| Depreciation and amortization | 240 |
| Prepaid expenses and other current assets | -483 |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | -157 |
| Operating lease liability | -1,376 |
| Net cash used in operating activities | -25,592 |
| Net cash from investing activities | 0 |
| Value of equity awards withheld for tax liability | 0 |
| Proceeds from exercise of common warrants, net of issuance costs | 557 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 37,940 |
| Net cash provided by financing activities | 38,497 |
| Increase (decrease) in cash and cash equivalents | 12,905 |
| Cash and cash equivalents at beginning of period | 8,714 |
| Cash and cash equivalents at end of period | 21,619 |
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)